Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 1.00 |
| ▸ | TFEB | P19484 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.84 |
| ▸ | NPC1 | O15118 | 3/20 | 0.84 |
| ▸ | RAB9A | P51151 | 2/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.84 |
| ▸ | ATM | Q13315 | 1/20 | 0.84 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.84 |
| ▸ | LY96 | Q9Y6Y9 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | BCHE | P06276 | 1/20 | 0.70 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | MAOB | P27338 | 3/20 | 0.64 |
| ▸ | AR | P10275 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.62 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744047 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL30307386 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL29805195 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL2744044 | 1.00 | NFE2L2 (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL28360791 | 0.92 | MAPT (1.00) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL16093028 | 0.92 | NFE2L2 (0.84) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL27034286 | 0.90 | NFE2L2 (0.81) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL609604 | 0.88 | NFE2L2 (0.78) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL609603 | 0.88 | NFE2L2 (0.78) | NFE2L2TFEBMAPTKDM4ENPC1 | |
| SCHEMBL28356941 | 0.87 | NFE2L2 (0.77) | NFE2L2TFEBMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004120-B1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | UNIV NANYANG TECH (SG) | 2018-08-29 | — | — | EP | disclosed |
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2016-05-19 | — | — | US | disclosed |
| EP-3004120-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | Nanyang Technological University (SG) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014196930-A1 | SPIRO-1,1'-BIINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALLADIUM-CATALYZED ASYMMETRIC HECK REACTION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136629-A1 | SPIRO-1,1'-BINDANE-7,7-BISPHOSPHINE OXIDES AS HIGHLY ACTIVE SUPPORTING LIGANDS FOR PALADIUM-CATALYZED ASYMMETRIC HECK REACTION | SBK1, SIK1, PDPK1 | NFE2L2 997/4885TFEB 3157/4885MAPT 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.